Precision Oncology News: Kinnate Exiting Stealth Mode With Plans to Move Lead RAF Inhibitor Into Clinical Trials Next Year

June 16, 2020

Most BRAF inhibitors that have been commercialized to date, or are being studied, go after BRAF V600 mutations, according to Kinnate CEO Nima Farzan. “We are looking after these class II, class III, or atypical mutations where the current drugs just do not work, and it’s a more complex problem to solve,” he said. “Our efforts have led us to believe that we can be effective in these other situations, where there are no approved drugs.”

To read the article, please visit Precision Oncology News.